Trading Signals: HTBX Stock Price Prediction and Forecast (Mon. Dec. 28, 2015 - Mon. May. 2, 2022)(Heat Biologics, Inc.)
| HTBX latest price $2.3800 (0%) ($2.3300 - $2.4800) on Mon. May. 2, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 4.86% (three month average) | RSI | 37 | Latest Price | $2.3800(0%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | HTBX declines -0.9% a day on average for past five trading days. | Weekly Trend | HTBX declines -9.4% a week on average for past two weeks. | Market Behavior | Growth stock rally for large cap. Growth stock rally for small cap. | Correlated ETFs | Broad market will support HTBX advance at 0% a week (0% probability) SLV(66%) SPLV(53%) VCSH(-32%) SIL(82%) SDY(56%) | Factors Impacting HTBX price | HTBX will decline at least -2.43% in a week (0% probabilities). ARKG(15%) MCHI(27%) EMHY(30%) IWC(44%) LQD(11%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.43% (StdDev 4.86%) | Hourly BBV | -0.3 () | Intraday Trend | -1.2% | | | |
|
1 - 5 Day Possible Target | $-15.38(-746.22%) | Resistance Level | $2.66 | 5 Day Moving Average | $2.33(2.15%) | 10 Day Moving Average | $2.45(-2.86%) | 20 Day Moving Average | $2.66(-10.53%) | To recent high | -24.4% | To recent low | 13.3% | Market Cap | $262m | | | | Heat Biologics, Inc. is a clinical stage company, which engages in the development of immunotherapies designed to activate and expand a patient's T-cell mediated immune system against cancer. The company's T-cell activating platform (TCAP) produces therapies designed to turn immunologically cold tumors to hot, and be administered in combination with checkpoint inhibitors and other immuno-modulators to increase clinical effectiveness. Its TCAP product candidates from the company's ImPACT and ComPACT platforms are produced from allogeneic cell lines expressing tumor-specific proteins common among cancers. The company was founded by Jeffrey Alan Wolf on June 10, 2008 and is headquartered in Morrisville, NC. |